CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+31%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.52B
AUM Growth
+$1.52B
(+28%)
Cap. Flow
+$100M
Cap. Flow
% of AUM
6.62%
Top 10 Holdings %
Top 10 Hldgs %
76.01%
Holding
46
New
6
Increased
11
Reduced
8
Closed
10
Top Buys
| 1 |
Illumina
ILMN
|
$73.5M |
| 2 |
Sarepta Therapeutics
SRPT
|
$63.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$36.2M |
| 4 |
Exact Sciences
EXAS
|
$16.8M |
| 5 |
Intellia Therapeutics
NTLA
|
$16.5M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$31.4M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$25.6M |
| 3 |
MaxCyte
MXCT
|
$21M |
| 4 |
Agios Pharmaceuticals
AGIO
|
$17.4M |
| 5 |
Tango Therapeutics
TNGX
|
$15.9M |
Sector Composition
| 1 | Healthcare | 99.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EQRX
1
DELISTED
EQRx, Inc. Common Stock
EQRX
| $196M | 12.85% | 39,527,669 | – | – |
|
2
BioLife Solutions
BLFS
$1.2B
| $172M | 11.31% | 7,566,292 | – | – |
|
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $135M | 8.9% | 1,225,000 +575,000 | +88% | +$63.6M |
|
|
4
Alnylam Pharmaceuticals
ALNY
$58.5B
| $130M | 8.52% | 648,000 -157,000 | -20% | -$31.4M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $112M | 7.36% | 1,700,000 +550,000 | +48% | +$36.2M |
|
|
VERV
6
DELISTED
Verve Therapeutics
VERV
| $109M | 7.17% | 3,178,167 +40,000 | +1% | +$1.37M |
|
7
Relay Therapeutics
RLAY
$619M
| $105M | 6.88% | 4,683,432 +614,858 | +15% | +$13.8M |
|
|
8
Illumina
ILMN
$15.8B
| $73.5M | 4.83% | +385,000 | New | +$73.5M |
|
|
9
MaxCyte
MXCT
$148M
| $69.8M | 4.58% | 10,735,786 -3,235,548 | -23% | -$21M |
|
10
Revolution Medicines
RVMD
$7.1B
| $49.7M | 3.27% | 2,522,300 +152,300 | +6% | +$3M |
|
11
Fate Therapeutics
FATE
$120M
| $45.9M | 3.02% | 2,050,000 -50,000 | -2% | -$1.12M |
|
|
SLGC
12
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $36.6M | 2.4% | 12,604,275 +215,193 | +2% | +$624K |
|
13
Century Therapeutics
IPSC
$42.5M
| $31.7M | 2.08% | 3,206,380 | – | – |
|
|
14
Exact Sciences
EXAS
$8.98B
| $31.4M | 2.06% | 967,000 +517,000 | +115% | +$16.8M |
|
15
Denali Therapeutics
DNLI
$2.23B
| $30.5M | 2.01% | 995,000 -505,000 | -34% | -$15.5M |
|
16
Absci
ABSI
$357M
| $24.2M | 1.59% | 7,718,593 | – | – |
|
17
Beam Therapeutics
BEAM
$1.66B
| $17.6M | 1.16% | 370,000 -5,000 | -1% | -$238K |
|
|
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $17.5M | 1.15% | 250,000 +153,000 | +158% | +$10.7M |
|
|
19
Intellia Therapeutics
NTLA
$1.22B
| $16.5M | 1.08% | +295,000 | New | +$16.5M |
|
20
AbCellera Biologics
ABCL
$1.25B
| $16.3M | 1.07% | 1,650,000 +900,000 | +120% | +$8.9M |
|
21
Pliant Therapeutics
PLRX
$101M
| $15.7M | 1.03% | +750,000 | New | +$15.7M |
|
22
GeneDx Holdings
WGS
$3.72B
| $14.4M | 0.95% | 16,437,500 | – | – |
|
23
Twist Bioscience
TWST
$1.63B
| $12.9M | 0.85% | 365,000 -135,000 | -27% | -$4.76M |
|
24
Tenaya Therapeutics
TNYA
$184M
| $10.4M | 0.68% | 3,586,818 | – | – |
|
|
TSVT
25
DELISTED
2seventy bio
TSVT
| $8.95M | 0.59% | 614,754 | – | – |
|